PD-L1 Expression in Lung Cancer.
PD-L1 Expression in Lung Cancer.
复制标题
DOI：
10.1016/j.jtho.2016.04.014
复制
发表时间：
2016-07
期刊：
影响因子：
--
通讯作者：
Hirsch FR
中科院分区：
文献类型：
--
作者：
Yu H;Boyle TA;Zhou C;Rimm DL;Hirsch FR
针对程序性死亡配体 1 (PD-L1) 及其受体 (PD-1) 的免疫疗法提高了部分晚期肺癌患者的生存率。 PD-L1 蛋白表达已成为预测哪些患者更有可能对免疫治疗产生反应的生物标志物。由于使用不同的免疫组织化学平台和不同的 PD-L1 抗体、评分系统以及不同的抗 PD-L1 和抗 PD-1 药物的免疫治疗临床试验的阳性截止值的历史，对 PD-L1 作为生物标志物的理解变得复杂。在此，我们总结了 PD-L1 作为生物标志物的简史，并描述了协调 PD-L1 检测和解释以实现最佳患者护理所面临的挑战。
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.